Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Boosted by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 9.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 9,653 shares of the company’s stock after acquiring an additional 814 shares during the period. SG Americas Securities LLC’s holdings in Dianthus Therapeutics were worth $210,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Dianthus Therapeutics in the third quarter worth approximately $556,000. Barclays PLC lifted its holdings in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares during the period. HighVista Strategies LLC bought a new position in Dianthus Therapeutics during the third quarter valued at about $542,000. State Street Corp lifted its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $23.05 on Friday. The stock has a market cap of $682.21 million, a PE ratio of -9.22 and a beta of 1.72. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.34 and a fifty-two week high of $33.77. The stock’s 50-day moving average is $23.04 and its two-hundred day moving average is $25.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of research reports. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, TD Cowen started coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.